Home > Boards > US Listed > Biotechs >

Can-Fite BioPharma (CANF)

Add CANF Price Alert      Hide Sticky   Hide Intro
Moderator: midastouch017
Search This Board: 
Last Post: 11/24/2020 7:52:33 AM - Followers: 63 - Board type: Free - Posts Today: 0

Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and liver diseases.

The company platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. The company compounds bind with nM affinity to the A3AR and initiate de-regulation of the NF-kB and the Wnt signal transduction pathways resulting in anti-inflammatory and anti-cancer effects


The company pipeline drugs are synthetic, highly specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile. Piclidenoson (CF101), Can-Fite`s lead drug candidate, is an oral drug that has been successfully tested in animal models and is currently in Phase III clinical studies for the treatment of Rheumatoid Arthritis (RA) and Psoriasis. All human clinical studies have demonstrated this drug to have an excellent safety profile. In two Phase II studies where Piclidenoson has been given as a standalone drug, data indicated that it acted as a disease modifying anti-inflammatory drug in RA patients. The Phase II and the Phase II/III clinical studies in Psoriasis showed clinical activity and safety of the drug. Namodenoson (CF102), Can-Fite`s second drug candidate, is an oral drug currently being developed for the treatment of Liver Diseases including hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH). CF602 an allosteric modulator at the A3AR which has shown proof of concept in pre-clinical pharmacology studies and is earmarked for the treatment of sexual dysfunction. Can-Fite has a wealth of clinical experience which includes over 1200 patients who have participated in clinical trials conducted by the company.

Can-Fite has licensed Piclidenoson for the treatment of autoimmune diseases to Cipher Pharmaceuticals in Canada, to Gebro Pharma GmbH in Spain, Switzerland & Austria,  for RA to Kwang Dong in Korea and to CMS for RA and Psoriasis in China, Taiwan, Hong Kong, Macao.

Can-Fite has licensed Namodenoson for the treatment of Liver Cancer and NASH to Chong Kun Dang Pharmaceut in Korea and to CMS in China.

Can-Fite is collaborating with leading researchers from the US NIH and the Leiden University in the Netherlands.


Israeli Office

10 Bareket Street
Kiryat Matalon
P.O. Box 7537
Petah-Tikva 49170
ISRAEL (Directions)

Tel: +972-3-9241114
Fax: +972-3-9249378

General email:


Investor Relations


USA Office

255 Bear Hill Road, Suite 2200
MA 02451

Tel: +972-3-9241114
Fax: +972-3-9249378



Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CANF News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 11/24/2020 07:08:15 AM
CANF News: Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting’ in the NASH Category of the American Associatio... 11/24/2020 07:00:00 AM
CANF News: Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET 11/23/2020 07:00:00 AM
CANF News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 11/16/2020 07:10:35 AM
CANF News: Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liv... 11/16/2020 07:00:00 AM
#1557  Sticky Note FDA Clears Can-Fite to Commence Phase II COVID-19 Study midastouch017 08/31/20 08:10:18 AM
#1597   Can-Fite’s Namodenoson Abstract Selected as ‘Best of The midastouch017 11/24/20 07:52:33 AM
#1596   Can-Fite to Conduct Investor Call to Review Q3 midastouch017 11/23/20 07:40:14 AM
#1595   Can-Fite Presented NASH Phase II Namodenoson Data at midastouch017 11/16/20 08:07:36 AM
#1594   Can-Fite to Present its NASH Program in Fireside midastouch017 11/09/20 08:41:10 AM
#1593   You know, some of market makers here were keekee 10/21/20 11:51:07 AM
#1592   I have invited the SEC to look at keekee 10/21/20 09:58:04 AM
#1591   "Improper co-ordination of trades by market makers creating keekee 10/21/20 09:56:47 AM
#1590   So many great biotechs that have run to dsscam 10/16/20 09:11:56 AM
#1589   Will be interesting to learn more on the Spideyboy 10/16/20 05:41:46 AM
#1588   Hard to tell.. seemed ho-hum.. just moving along drmaddogs2 10/15/20 05:56:12 PM
#1587   CANF: why sudden drop near CC call? swampboots 10/15/20 05:43:34 PM
#1586   Can anyone short story the terrible accent in drmaddogs2 10/15/20 05:17:07 PM
#1585   First comes tomorrow, positive midastouch017 10/14/20 11:47:15 AM
#1584   should hear some covid19 update news soon peterus 10/14/20 10:21:47 AM
#1583   Can-Fite to update on late-stage psoriasis study on midastouch017 10/13/20 08:09:22 AM
#1582   Can-Fite to Host Conference Call to Update Shareholders midastouch017 10/13/20 07:59:32 AM
#1581   Until these companies begin to take some hard keekee 10/13/20 07:32:21 AM
#1580   Poor Canfite....company has no idea the fraud its keekee 10/13/20 07:27:23 AM
#1579   Nice to see the news on the Psoriasis Spideyboy 10/08/20 04:57:48 AM
#1578   Great news, but with several crime families parading keekee 10/06/20 08:55:32 AM
#1577   Can-Fite Bio on go with late-stage study with midastouch017 10/06/20 08:22:22 AM
#1576   Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis midastouch017 10/06/20 07:38:09 AM
#1575   CANF day will come, midastouch017 09/30/20 12:47:38 PM
#1574   $35 billion news and the single player news keekee 09/30/20 10:35:07 AM
#1573   Can-Fite Selected to Deliver Late-Breaking Oral Presentation on midastouch017 09/30/20 08:10:48 AM
#1572   CANF 16:39 09/25/20 midastouch017 09/26/20 02:38:43 AM
#1571   Can-Fite to Participate in Two BioPharma Partnering Conferences midastouch017 09/22/20 08:04:18 AM
#1570   Learn About Can-Fite BioPharma (NYSE American: CANF) in midastouch017 09/18/20 11:45:27 AM
#1569   CANF / Can-Fite Biopharma Ltd. - Institutional Ownership midastouch017 09/12/20 11:37:59 AM
#1568   Can-Fite to Present at H.C. Wainwright 22nd Annual midastouch017 09/08/20 08:07:03 AM
#1567   What doesn't? midastouch017 09/04/20 11:56:36 AM
#1566   CANF: and yet price collapse? swampboots 09/04/20 11:41:14 AM
#1565   The European Patent Office Notifies Can-Fite Biopha (NYSEAMERICAN:CANF) midastouch017 09/03/20 12:52:49 PM
#1564   But an impediment for one industry can create midastouch017 09/03/20 05:28:18 AM
#1563   I would not be surprised to see CANF midastouch017 09/02/20 09:00:59 AM
#1562   Analysts at Maxim Group assigned CANF a rating midastouch017 09/02/20 08:52:56 AM
#1561   CANF jeffp123 09/02/20 08:44:15 AM
#1560   Maybe you should read some posts under my keekee 08/31/20 12:30:50 PM
#1559   2.23s she ready to go peterus 08/31/20 09:55:21 AM
#1558   good news and red !!! market is going crazy peterus 08/31/20 09:52:52 AM
#1557   FDA Clears Can-Fite to Commence Phase II COVID-19 Study midastouch017 08/31/20 08:10:18 AM
#1556   golden cross lol peterus 08/31/20 07:37:56 AM
#1555   FDA NEWS OUT,,,safe to proceed kingsransome 08/31/20 07:21:02 AM
#1554   $CANF / #CanFite #Biopharma Long Into Earnings TFMG 08/30/20 02:46:03 PM
#1553   Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on midastouch017 08/28/20 12:06:44 AM
#1552   Can-Fite Reports Second Quarter 2020 Financial Results & midastouch017 08/27/20 07:52:28 AM
#1551   Indeed, one final FDA phase III approval to midastouch017 08/26/20 11:56:21 AM
#1550   great pipelineeeee should trade match higher peterus 08/26/20 11:50:14 AM
#1549   Check this: midastouch017 08/26/20 10:59:58 AM
#1548   in pr AND TWO UPCOMING CLINICAL TRIALS IN THE peterus 08/26/20 10:53:25 AM
Consent Preferences